



Dear Fellow Physicians,

I am writing to let you know that I am participating as a Principal Investigator in a clinical research study for adults diagnosed with relapsing multiple sclerosis (MS). This global study is being conducted to provide data in support of regulatory approval worldwide of ofatumumab, a subcutaneously (SC) administered human anti-CD20 monoclonal antibody. As a fellow physician in the community who sees adults with MS, you may be interested in referring patients to me to take part in this important study.

About ASCLEPIOS

Sponsored by Novartis Pharmaceuticals Corporation, the ASCLEPIOS program includes 2 pivotal studies of identical design (ClinicalTrials.gov ID NCT02792231/NCT02792218). My site is participating in one of these studies. The study aims to evaluate if ofatumumab, at monthly SC doses of 20 mg, is superior to teriflunomide 14 mg once daily orally in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in patients with relapsing MS. The study is a double-blind, double-dummy, active-comparator controlled study, with a variable treatment duration where maximum individual treatment duration is 30 months. The study will involve about 900 adult patients who will take both a daily oral capsule and a monthly SC injection (double-dummy design).

To qualify for the study, patients must be:

- Male or female aged 18 to 55 years, inclusive
- Diagnosed with relapsing MS with at least one relapse during the previous year or two relapses in the previous two years or have a positive Gd-enhancing MRI scan in the last year

To Learn More

To learn more about ASCLEPIOS, or if you would like to discuss any prospective patients, please contact me at [insert phone number]. Please be assured that if any of your patients should qualify for the study, I will remain in regular contact to update you on their participation in the study.

Thank you for considering the ASCLEPIOS study for your patients. I look forward to hearing from you.

Sincerely,

Neurologist Dr. Ken Sharlin
Sharlin Health & Neurology